Mobile Site ›
Print Friendly View

Test ID: FPMET    
Prometheus Thiopurine Metabolites

Available on the App Store

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Units of Measure:  pmol/8 x 10(8) RBC

 

Metabolite                                                   Reference Range

6-TGN                                                                 230-400

6-MMPN                                                              <5700

 

Proprietary and patented technology by Prometheus Laboratories,

Inc.  The therapeutic range and toxic thresholds were established

in  an IBD patient population receiving azathioprine or

6-mercaptopurine.  Metabolite testing should not replace

laboratory monitoring for toxicity.

 

Graph available upon request.

 

Test Performed By:   Prometheus Laboratories, Inc.

                                        Therapeutics and Diagnostics

                                        9410 Carroll Park Drive

                                        San Diego, CA  92121-4203

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

Dubinsky M, et al. Pharmacogenomics and metabolite

measurement for 6-mercaptopurine therapy in patients with

inflammatory bowel disease.  Gastroenterology.  2000;118:705-713.

 

Seidman EG. Recent Advances in the diagnosis and treatment

of pediatric inflammatory bowel disease.  Gastroenterol Rep.2000;

1:248-252.

 

Cuffari C, et al. Utilisation of erythrocyte 6-thioguanine metabolite

levels to optimize azathioprine therapy in patients with inflammatory

bowel disease. Gut. 2001;48:642-646.

 

Seidman, EG. Clinical use and practical application of TPMT Enzyme

and 6-mercaptopurine metabolite monitoring in IBD. Rev

Gastroenterol Disord. 2003;3(suppl 1):S30-S38.

 

Rumbo C, et al. Azathioprine metabolite measurements in the

treatment of autoimmune hepatitis in pediatric patients: A preliminary

report. J Ped Gastro Nutr. 2002;35:391-398.

 

Lennard L, et al. The clinical pharmacology of 6-mercaptopurine.

Eur J Clin Pharmacol. 1992;43(4):329-339.

 

Lennard L. Clinical implication of thiopurine methyltransferase-Optimization

of drug dosage and potential drug interactions. Ther Drug Monit 1998;

20(5):527-531.

 

Louis E, Belaiche J. Optimizing treatment with thioguanine derivative

in inflammatory bowel disease.  Best Pract Res Clin Gastroenterol

2003;17(1):37-46.